Pfizer confirms effectiveness of vaccine against Covid-19
The company, together with Biontech, announced that the drug developed by both is 90 % effective
Pfizer and Biontech announced that their Covid-19 vaccine is more than 90 % effective, following the “success” of the first interim analysis of their phase 3 trial.
Thus, its candidate for a vaccine based on mRNA, BNT162b2 against SARS-COV-2, confirmed its efficacy against the coronavirus in participants without previous evidence of infection, according to the first provisional efficacy analysis carried out on November 8th.
The tests were conducted on a total of 43,538 participants and the analysis has evaluated 94 confirmed cases of Covid-19 in trial participants.
Following these results, Pfizer President and CEO Albert Bourla said it is “a great day for science and humanity. The first results from our Phase 3 Covid-19 vaccine trial provide initial evidence of the ability to prevent the disease.”
Pfizer president insisted that the first interim analysis of its global phase 3 study “provides evidence that a vaccine can effectively prevent Covid-19. This is a victory for innovation, science and a global collaborative effort.”
Based on current projections, the company expects to produce up to 50 million doses of vaccines globally in 2020 and up to 1.3 billion doses in 2021.
K. Tovar
Source: Panorama
